Gastrointestinal Cancer | Specialty

The gastrointestinal cancer condition center is a comprehensive resource for clinical news and expert insights on gastrointestinal cancer. Read more at OncLive.

PLN-101095 Plus Pembrolizumab Displays Activity in ICI-Refractory Advanced Solid Tumors

December 4th 2025

PLN-101095 in combination with pembrolizumab led to responses in patients with ICI-refractory advanced solid tumors.

PIPAC Reshapes Peritoneal Cancer Surgery Workflows and Outcomes: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; Benjamin Jon Golas, MD, FACS; and Eric Pletcher, MD

December 3rd 2025

Drs Tiesi, Scholer, Golas, and Pletcher discussed the use of PIPAC, a minimally invasive regional cancer therapy, in patients with peritoneal cancers.

Revisit Every OncLive On Air Episode From November 2025

December 2nd 2025

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.

OncLive’s November Roundup of Key FDA Approvals in Oncology: 10 Decisions to Know

December 2nd 2025

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

Personalized Treatment Considerations Guide First-Line Chemo Use in Pancreatic Cancer: With Shubham Pant, MD, MBBS

December 2nd 2025

Dr Pant discusses factors that drive frontline chemotherapy selection for metastatic pancreatic cancer and the role of NALIRIFOX in this treatment setting.

Experts Unpack the Most Notable NCCN Guideline Changes Heading Into 2026

December 1st 2025

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.

Emerging Immunotherapy and Precision Medicine Strategies Take Aim at PDAC Treatment Resistance

November 30th 2025

Jose Trevino, MD, discusses how immunotherapy and precision medicine approaches may advance treatment for patients with immune-resistant PDAC.

The OncFive: Top Oncology Articles for the Week of 11/23

November 29th 2025

The FDA approved a new option in resectable gastric cancer, and a new agent is under priority review in mantle cell lymphoma.

Advancing Early Detection and Therapeutic Innovation Remain Critical in Pancreatic Ductal Adenocarcinoma

November 28th 2025

Jose Trevino, MD, discusses unmet needs in PDAC, highlighting early detection and multidisciplinary care amid Pancreatic Cancer Awareness Month.

FDA Approves Perioperative Durvalumab for Resectable Gastric/GEJ Adenocarcinoma

November 25th 2025

The FDA approved durvalumab plus FLOT for the perioperative treatment of resectable gastric and gastroesophageal junction cancers.

FDA Grants Orphan Drug Designation to OBI-902 in Cholangiocarcinoma

November 25th 2025

OBI-902 received orphan drug designation from the FDA for the treatment of patients with cholangiocarcinoma.

Targeting OXPHOS With Lixumistat Could Lessen Chemoresistance in Pancreatic Cancer

November 20th 2025

Shubham Pant, MD, MBBS, and Ryan W. Huey, MD, MS, discuss OXPHOS pathway inhibition in pancreatic cancer with lixumistat.

FDA Grants Fast Track Designation to DPTX3186 for Gastric Cancer

November 18th 2025

DPTX3186, a first-in-class oral condensate modulator, has received FDA fast track designation in gastric cancer.

Zanidatamab Plus Chemo ± Tislelizumab Impresses in HER2+ Gastroesophageal Adenocarcinoma

November 17th 2025

Zanidatamab-based regimens improved PFS and OS vs chemotherapy in HER2+ gastroesophageal adenocarcinoma, positioning the agent as a potential new standard.

The OncFive: Top Oncology Articles for the Week of 11/9

November 15th 2025

The FDA has approved ziftomenib for NPM1-positive acute myeloid leukemia, has accepted a NDA for 177Lu-edotreotide for GEP-NETs, and more.

FDA Accepts NDA For 177Lu-edotreotide for GEP-NETs

November 13th 2025

The NDA seeking approval of 177Lu-edotreotide for the treatment of patients with GEP-NETs has been accepted by the FDA.

Bezuclastinib Plus Sunitinib Shows PFS Benefit in Second-Line GIST

November 10th 2025

The phase 3 PEAK trial met its primary PFS end point with bezuclastinib plus sunitinib in imatinib-resistant/intolerant gastrointestinal stromal tumors.

Chan Breaks Down the Need for Dose Escalation With Somatostatin Analogs in GEP-NETs

November 8th 2025

Jennifer Chan, MD, MPH, discusses dose escalation and interval shortening with somatostatin analogs for GEP-NETs and how SORENTO may shape treatment.

177Lu-edotreotide Displays Efficacy Benefit Across Subgroups in Grade 1/2, SSTR+ GEP-NETs

November 6th 2025

Treatment with 177Lu-edotreotide was linked to improvements in PFS and ORR across subgroups of patients with SSTR-positive GEP-NETs.

GEP-NET–Focused Research Refines Optimal PRRT Use in Well-Differentiated Disease

November 5th 2025

Rohit Thummalapalli, MD, discusses the treatment paradigm for patients with GEP-NETs and the role of Lutetium Lu 177 dotatate across lines of therapy.